More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

A roundup of recent key investments and deals from contract manufacturing organizations and contract development and manufacturing organizations. This year has seen some noteworthy investments and deals among contract service providers and...
DCAT Value Chain Insights

CEO confidence in the US economy is improved although uncertainty remains for the rest of the world. So what is in the minds of CEOs? How do they view the performance and near-term outlook of the global and US economies and how are these views...
DCAT Value Chain Insights

Roche took the top position in a recently released measure of sustainability performance, with Amgen, GlaxoSmithKline, and Baxter among other companies making the grade. The annual rankings of the Dow Jones Sustainability Index (DJSI), which...
DCAT Value Chain Insights

Bayer is making a large statement with recent moves to fortify its pharmaceutical business. Its $14.2 billion acquisition of Merck & Co.'s consumer healthcare business last week is the company's latest. Bayer announced last month its plan to...
DCAT Value Chain Insights

Encouraged by governmental and regulatory initiatives and the need to combat antibiotic-resistant bacteria, the large pharmaceutical companies and specialty players target antibiotic innovation. President Obama's announcement last week to develop...
DCAT Value Chain Insights

Partnering is a vital vehicle to drive innovation and eventual commercialization. So what are some of the most promising deals thus far in 2014? One important measure of pharmaceutical industry activity is the level of partnering activity among...